Have a personal or library account? Click to login
Increased IL-33 and IL-17 in Colorectal Carcinoma Patients with Severe Disease Cover

Increased IL-33 and IL-17 in Colorectal Carcinoma Patients with Severe Disease

Open Access
|Dec 2020

References

  1. 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer 3 statistics, 2012.CA Cancer J Clin 2015;65:87-108.10.3322/caac.21262
  2. 2. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350-1356.10.1038/nm.3967
  3. 3. Jiang Q, Ma L, Li R, Sun J. Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity. Oncotarget 2017;9:11989-1199810.18632/oncotarget.22857
  4. 4. Zou S, Fang L, Lee MH. Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol Rep (Oxf) 2018;6:1-12.10.1093/gastro/gox031
  5. 5. Zou S, Fang L, Lee MH. Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cell Mol Gastroenterol Hepatol 2018;6:257-276.10.1016/j.jcmgh.2018.05.006
  6. 6. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013;39:1003-1018.10.1016/j.immuni.2013.11.010
  7. 7. Günther S, Deredge D, Bowers AL, Luchini A, Bonsor DA, Beadenkopf R, Liotta L, Wintrode PL, Sundberg EJ. IL-1 Family Cytokines Use Distinct Molecular Mechanisms to Signal through Their Shared Co-receptor. Immunity 2017;47:510-523.10.1016/j.immuni.2017.08.004
  8. 8. Wasmer M-H, Krebs P. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Frontiers in Immunology 2016;7:682.10.3389/fimmu.2016.00682
  9. 9. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol 2011;187:1609-1616.10.4049/jimmunol.1003080
  10. 10. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995;3:811-821.10.1016/1074-7613(95)90070-5
  11. 11. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, Pan G, Gurney AL, de Vos AM, Starovasnik MA. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001;20:5332-5341.10.1093/emboj/20.19.533212564611574464
  12. 12. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-174.10.1016/S1359-6101(03)00002-9
  13. 13. Gaffen SL. Biology of recently discovered cytokines: interleukin-17--a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res Ther 2004;6:240-247.10.1186/ar1444
  14. 14. Michel ML, Mendes-da-Cruz D, Keller AC, Lochner M, Schneider E, Dy M, Eberl G, Leite-de-Moraes MC. Critical role of ROR-γt in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc Natl Acad Sci U S A 2008;105:19845-51980.10.1073/pnas.0806472105
  15. 15. Ciric B, El-behi M, Cabrera R, Zhang GX, Rostami A. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 2009;182:5296-5305.10.4049/jimmunol.0900036
  16. 16. O’Brien RL, Roark CL, Born WK. IL-17-producing gammadelta T cells. Eur J Immunol 2009;39:662-666.10.1002/eji.200839120
  17. 17. Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Maric V, Arsenijevic A, Jovanovic I. Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma. Mediators Inflamm 2018;2018:8031328.10.1155/2018/8031328
  18. 18. Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Mirkovic D, Milev B, Maric V, Arsenijevic N. Fecal galectin-1 as a potential marker for colorectal cancer and disease severity. Vojnosanit Pregl (2018); DOI: https://doi.org/10.2298/VSP171201007J.10.2298/VSP171201007J
  19. 19. Hamilton SR and Aaltonen LA. Pathology and genetics:tumours of the digestive system, in World Health Organization Classification of Tumours, IARC, Lyon, France, 3rd edition, 2000. 103-143.
  20. 20. Lanza G, Messerini L, Gafa R, Risio M. Colorectal tumors: the histology report. Dig Liver Dis 2011;43 Suppl 4:S344-355.10.1016/S1590-8658(11)60590-2
  21. 21. Heilmann RM, Cranford SM, Ambrus A, Grützner N, Schellenberg S, Ruaux CG, Suchodolski JS, Steiner JM. Validation of an enzyme-linked immunosorbent assay (ELISA) for the measurement of canine S100A12. Vet Clin Pathol 2016;45:135-47.10.1111/vcp.1232026765807
  22. 22. Prakash N, Stumbles P, Mansfield C. Initial Validation of Cytokine Measurement by ELISA in Canine Feces. Open Journal of Veterinary Medicine 2013;3:282-288.10.4236/ojvm.2013.36046
  23. 23. Jovanovic M, Zdravkovic N, Jovanovic I, Radosavljevic G, Gajovic N, Zdravkovic N, Maric V, Arsenijevic N. TGF-β as a marker of ulcerative colitis and disease severity. Ser J Exp Clin Res DOI: 10.1515/sjecr-2017-0019.10.1515/sjecr-2017-0019
  24. 24. Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sørbye SW, Goll R, Florholmen J. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother 2015;64:181-190.10.1007/s00262-014-1624-x25324197
  25. 25. Mertz KD, Mager LF, Wasmer MH, Thiesler T, Koelzer VH, Ruzzante G, Joller S, Murdoch JR, Brümmendorf T, Genitsch V, Lugli A, Cathomas G, Moch H, Weber A, Zlobec I, Junt T, Krebs P. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology 2015;5:e1062966.10.1080/2162402X.2015.1062966476034326942077
  26. 26. Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008;14:5584-5589.10.3748/wjg.14.5584274634718810778
  27. 27. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.10.1053/gast.2000.852310889150
  28. 28. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506-513.10.1136/gut.47.4.506172806010986210
  29. 29. Johne B, Kronborg O, Tøn HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001;36:291-296.10.1080/003655201750074618
  30. 30. Fang M, Li Y, Huang K, et al. IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. Cancer Res 2017;77:2735-2745.10.1158/0008-5472.CAN-16-1602576017028249897
  31. 31. Li Y, Shi J, Qi S, Zhang J, Peng D, Chen Z, Wang G, Wang Z, Wang L. IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE(2). J Exp Clin Cancer Res 2018;37:196.10.1186/s13046-018-0839-7609864030119635
  32. 32. Zhang Y, Zoltan M, Riquelme E, et al. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology 2018;155:210-223.10.1053/j.gastro.2018.03.041603507529604293
  33. 33. He Z, Chen L, Souto FO, Canasto-Chibuque C, Bongers G, Deshpande M, Harpaz N, Ko HM, Kelley K, Furtado GC, Lira SA. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc (Min/+) mice. Sci Rep 2017;7:5520.10.1038/s41598-017-05716-z551121628710436
  34. 34. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol 2014;5:514.10.3389/fimmu.2014.00514
  35. 35. Zhang Y, Davis C, Shah S, Hughes D, Ryan JC, Alto-mare D, Peña MM. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog 2017;56:272-287.10.1002/mc.22491563013627120577
  36. 36. Akimoto M, Maruyama R, Takamaru H, Ochiya T, Takenaga K. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment. Nat Commun 2016;7:13589.10.1038/ncomms13589512305727882929
  37. 37. Akbay EA, Koyama S, Liu Y, et al. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol 2017;12:1268-1279.10.1016/j.jtho.2017.04.017553206628483607
  38. 38. Chen Y, Yuan R, Wu X, He X, Zeng Y, Fan X, Wang L, Wang J, Lan P, Wu X. A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer. Ann Surg Oncol 2016;23:826-832.10.1245/s10434-015-4889-126581202
  39. 39. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z, Zhu B. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011;407:348-354.10.1016/j.bbrc.2011.03.02121396350
  40. 40. Kyung-Ah Cho, Jee Won Suh, Jung Ho Sohn, Jung Won Park, Hyejin Lee, JiHee Lee Kang, So-Youn Woo, and Young Joo Cho. IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol 2012;302:429-440.10.1152/ajplung.00252.201122180658
DOI: https://doi.org/10.2478/sjecr-2018-0034 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454
Language: English
Page range: 239 - 245
Submitted on: Sep 3, 2018
|
Accepted on: Sep 5, 2018
|
Published on: Dec 21, 2020
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Veljko Maric, Milan Jovanovic, Natasa Zdravkovic, Marina Jovanovic, Nevena Gajovic, Milena Jurisevic, Marina Jovanovic, Ivan Jovanovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.